
FDA Grants First-Ever Approval for KRAS-Mutated Recurrent Ovarian Cancer Treatment
The FDA has granted accelerated approval to the combination therapy of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for adults with KRAS-mutated, recurrent low-grade serous ovarian cancer who have previously undergone systemic therapy. This marks …